VDR rs7313816: TaqI Variant and Vitamin D Dynamics
The rs7313816 variant, historically referred to as the TaqI restriction site polymorphism, is a single-nucleotide variant in the Vitamin D Receptor (VDR) gene. Scientific literature has frequently investigated this variant for its statistical associations with bone mineral density, calcium homeostasis, and individual variability in response to vitamin D supplementation. Because it does not change the resulting amino acid sequence, researchers hypothesize that it subtly influences gene expression or acts as a genetic marker for nearby regulatory variations.
What each genotype means
Typical vitamin D receptor profile
You carry two copies of the T allele at this locus, traditionally referred to in older restriction enzyme research as the 'T' allele of the TaqI polymorphism. Research investigating this genotype shows mixed and population-specific findings regarding bone mineral density, metabolic traits, and vitamin D supplementation response. Because scientific evidence remains limited and conflicting, this genotype does not determine nutritional status or bone health on its own.
Carried by approximately 35% to 45% of individuals of European ancestry, and is common across many global populations.
Intermediate vitamin D response profile
You carry one copy of the C allele and one copy of the T allele at this VDR locus. Some meta-analyses suggest that carrying a C allele (often reported as the variant or lowercase 't' allele in restriction fragment length polymorphism notation) may correlate with slight differences in vitamin D supplement responsiveness or bone turnover markers, though findings vary widely across ethnic backgrounds. Any decisions regarding vitamin D supplementation or bone health monitoring should be discussed with a qualified healthcare provider.
Carried by roughly 40% to 50% of individuals of European ancestry, representing the most common heterozygous genotype.
Altered vitamin D receptor expression
You carry two copies of the C allele, which represents the homozygous minor genotype at this site (often designated as 'tt' in classical restriction digest studies). Some clinical studies have associated this genotype with altered VDR mRNA stability and differential serum response to vitamin D supplementation, though broad clinical relevance remains inconclusive and heavily dependent on broader haplotypes such as BsmI and ApaI. You should discuss your specific vitamin D levels and dietary requirements with a clinician or registered dietitian rather than altering supplementation independently.
Carried by approximately 15% to 20% of people of European ancestry, with varying frequencies across other global ancestries.
Genomic Location and the TaqI Restriction Site
The single-nucleotide polymorphism rs7313816 is situated in exon 9 near the 3-prime untranslated region of the Vitamin D Receptor (VDR) gene on chromosome 12. In canonical genomic databases, it represents a transition where either a thymine (T) or a cytosine (C) nucleotide is present. Classical molecular biology literature frequently designates this variant as the TaqI polymorphism because the sequence change creates or abolishes a specific recognition site for the TaqI restriction enzyme. When the enzyme cuts the sequence, the allele is traditionally designated with a lowercase 't', whereas the absence of the cut site corresponds to the uppercase 'T'. At the protein level, rs7313816 is considered a synonymous change (often denoted as Ile352Ile), meaning it does not alter the encoded amino acid sequence of the receptor. Because the primary structure of the receptor protein remains unchanged, scientific interest centers on whether this nucleotide change alters messenger RNA stability, influences translation efficiency, or simply reflects linkage disequilibrium with other functionally significant variants located nearby in the genome.
Biological Role of the Vitamin D Receptor
The VDR gene encodes the vitamin D nuclear receptor, an essential transcription factor that mediates the biological actions of the active form of vitamin D, 1,25-dihydroxyvitamin D3. Upon binding its ligand, VDR forms a heterodimer with the retinoid X receptor (RXR) and binds to specific vitamin D response elements in regulatory regions across the human genome. This complex regulates hundreds of genes involved in systemic mineral balance, including intestinal calcium and phosphate absorption, renal calcium reabsorption, and dynamic bone remodeling. Beyond skeletal biology, the vitamin D receptor is expressed across numerous tissues, including immune cells, endothelial walls, and metabolic organs. As a result, variations within the VDR gene have captured substantial attention in nutrigenomics and epidemiologic research, as subtle alterations in receptor expression or regulation could theoretically modulate downstream immune responses, cellular differentiation, and systemic inflammatory pathways across diverse environmental contexts.
Scientific Evidence and Phenotypic Associations
Numerous candidate gene association studies and meta-analyses have examined whether rs7313816 correlates with traits such as bone mineral density, osteoporotic fracture risk, and serum 25-hydroxyvitamin D elevation following supplementation. Systematic reviews have reported that individuals carrying the variant C allele (often corresponding to the 't' restriction allele) may exhibit slightly higher increases in serum vitamin D levels in response to standard supplementation protocols compared to homozygous T carriers. Other observational investigations have linked the polymorphism to differences in bone mineral density at the lumbar spine or femoral neck, as well as minor shifts in susceptibility to infectious or autoimmune conditions. However, the overall strength of evidence remains limited and conflicting. Many reported associations fail to reach statistical significance in large-scale genome-wide association studies (GWAS), and reported effect sizes are modest. Discrepancies across publications are likely driven by small cohort sizes, uncontrolled dietary calcium and sunlight exposure, and substantial differences in genetic background across studied cohorts.
Interpreting Genetic Data Responsibly
Discovering one's genotype at rs7313816 provides educational insight into common human genetic variation, but it is not a standalone diagnostic or predictive tool. Possessing a particular genotype does not confirm that an individual has vitamin D deficiency, low bone mineral density, or altered calcium absorption. Because rs7313816 has limited clinical evidence and modest effect sizes, clinical guidelines do not recommend altering dietary intake or vitamin D supplement dosing based solely on this genotype. Vitamin D nutritional status is overwhelmingly shaped by modifiable and environmental factors, such as dietary choices, sun exposure, geographical latitude, age, and gastrointestinal absorption. Any consumer interested in evaluating their vitamin D status should consult a primary care clinician to obtain an objective serum 25-hydroxyvitamin D blood test, and any changes in supplementation or therapeutic dosing should be supervised by a healthcare provider or pharmacist.
How common is this variant?
The minor allele (C) frequency is observed at approximately 0.35 to 0.45 in populations of European ancestry, with the homozygous CC genotype present in roughly 10% to 20% of individuals. Frequency distributions vary considerably across other ancestral backgrounds, including South Asian, East Asian, and African populations.
Frequently asked questions
What does the TaqI notation mean for rs7313816?
TaqI refers to a bacterial restriction enzyme historically used in genetic laboratories to cut DNA at specific sequences. For the rs7313816 marker, the presence of the C nucleotide creates a cutting site (traditionally written as allele 't'), whereas the T nucleotide lacks this site (written as allele 'T').
Does having rs7313816 mean I need higher vitamin D supplements?
No. Genetic variants in the VDR gene only explain a tiny fraction of the variation in vitamin D levels. You should not start, stop, or change dietary supplement doses based on a direct-to-consumer genetic test; any supplementation plan should be guided by a serum blood test reviewed with your physician.
Can rs7313816 diagnose osteoporosis or bone disease?
No, this single-nucleotide variant is not a diagnostic marker for osteoporosis, rickets, or any bone disorder. Bone density is a complex trait influenced by overall diet, physical activity, hormones, age, and hundreds of genetic loci across the genome.
Why is the evidence for rs7313816 described as limited?
While early candidate gene studies found statistical associations between this variant and bone density or vitamin D response, larger genome-wide association studies (GWAS) have demonstrated very small or inconsistent effects. Furthermore, factors like lifestyle, diet, and sunlight play a far larger role in vitamin D status than this single variant.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7313816?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VDR
Variant in the promoter region (Cdx2 site) of the vitamin D receptor gene associated with altered intestinal calcium absorption and bone mineral density.
This variant in the Vitamin D receptor gene is associated with susceptibility to Type 1 Diabetes and autoimmune thyroid disease.
Promoter polymorphism (Cdx2) in the VDR gene associated with bone mineral density and vitamin D metabolism.
Common polymorphism (TaqI variant) in the vitamin D receptor affecting mRNA stability and bone mineral density.
Known as the TaqI polymorphism, this variant is located in the 3' UTR of the VDR gene and is associated with altered mRNA stability, influencing vitamin D signaling, cancer cachexia susceptibility, and gastric cancer risk.
Variant in the VDR promoter (Cdx-2 binding site) associated with bone mineral density and calcium absorption efficiency.